Effectiveness of KOS-862 in the Treatment of Lung Cancer
Phase 2
Terminated
- Conditions
- Lung Cancer
- Registration Number
- NCT00080509
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.
- Detailed Description
To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
- At least 18 years of age
- Measurable disease
- One previous treatment of a platinum based drug such as cisplatin or carboplatin
- At least 3 weeks since last surgery/radiation/chemotherapy
Exclusion Criteria
- Brain metastases
- Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method NSCLC
- Secondary Outcome Measures
Name Time Method